Author

Ying Yi

ORCID 0000-0003-1434-1458Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Yasser PereraiD· 2 shared Arielis Rodríguez‐UlloaiD· 1 shared Dongfang Tang· 1 shared Jiale XieiD· 1 shared Lingfeng Dai· 1 shared Liudy García HernándeziD· 1 shared Luis Javier GonzáleziD· 1 shared Meifeng WangiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Yasser PereraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyBiological ChemistryPeer-reviewedMar 1, 2025

Time- and Dose-dependent Effects of CIGB-300 in the lung squamous cell carcinoma proteomics.

Liudy García Hernández, Lingfeng Dai, Arielis Rodríguez‐Ulloa…·Yasser Perera

This study examines the time- and dose-dependent effects of CIGB-300 on the proteome of squamous lung cancer cells, identifying potential biomarkers and mechanisms of action.

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 24, 2024

CIGB-300 reverses chemo-resistance in MDR1-transfected lung squamous cancer cells

Meifeng Wang, Dongfang Tang, Xiaofang Luo…·Zuodong Qin

This study shows that CIGB-300 reverses multidrug resistance in ABCB1-overexpressing lung cancer cells by inhibiting ABCB1 expression and related signaling pathways.

DOI 10.1101/2024.10.24.620006

humanproteomics

𝕏 PostBluesky